Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study finds

Adding the oral selective Janus kinase 1 and 2 inhibitor, baricitinib, to topical corticosteroid treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis, a phase III study in JAMA Dermatology has suggested.

Source link

Share and Enjoy !

0 0